U.S. Chemicals Stock News

Ameriprise Financial (AMP) is back in focus after reporting first quarter 2026 assets under management, administration, and advisement of US$1.7b and spotlighting a new retail investment program relationship with Huntington National Bank. See our latest analysis for Ameriprise Financial. The recent Huntington relationship and advisor leadership changes arrive while the stock is consolidating, with the share price down 9.4% year to date and the 1 year total shareholder return down 11.2%, even...

eBay stock’s recent performance in context eBay (EBAY) has quietly outperformed many retail-focused stocks recently, with the share price up 6.0% over the past month and 23.1% over the past 3 months. This has drawn fresh attention from investors reviewing online marketplace exposure. See our latest analysis for eBay. Looking beyond the recent rally, eBay’s 1 day share price return of 0.99% and year to date share price return of 26.75% sit alongside a 1 year total shareholder return of 49.96%...

Recent performance snapshot Marten Transport (MRTN) has drawn fresh attention after a strong recent share performance. The stock is up 1.8% in the latest session, about 15.8% over the past month, and 29.8% in the past 3 months. See our latest analysis for Marten Transport. Beyond the recent bounce, the stock shows strong momentum, with a 7 day share price return of 5.2%, a 30 day share price return of 15.8% and a year to date share price return of 53.3%. The 1 year total shareholder return of...

In late May 2026, Hormel Foods reported second-quarter results showing sales of US$2,972.6 million and lower year-on-year earnings, while also reducing its full-year 2026 diluted EPS guidance range to US$1.28–US$1.37 but maintaining expected net sales of US$12.2–US$12.5 billion and operating income of US$0.96–US$1.02 billion, including the loss on the sale of its whole-bird turkey business. Despite the softer profitability outlook, Hormel’s combination of six consecutive quarters of organic...

Why Delek US Holdings Is Back on Investors’ Radar Delek US Holdings (DK) has drawn fresh attention after highlighting progress on its Enterprise Optimization Plan, completing the Big Spring refinery turnaround on schedule and on budget, and continuing the ramp-up of the Delaware basin Libby 2 Plant. See our latest analysis for Delek US Holdings. The recent 3.3% one day share price return and 5.2% 7 day share price return suggest investors are responding to the turnaround progress. A 54.3%...

On May 21, 2026, Vertex Pharmaceuticals announced that Health Canada accepted for review a New Drug Submission for suzetrigine, a first-in-class, non-opioid, non-NSAID oral NaV1.8 inhibitor for moderate-to-severe acute pain in adults, following its earlier U.S. approval as JOURNAVX. This regulatory step, alongside FDA review progress for Vertex’s immunoglobulin A nephropathy candidate povetacicept, highlights the company’s effort to expand beyond cystic fibrosis into broader pain and kidney...

Event driven interest in Hyperliquid Strategies Hyperliquid Strategies (PURR) is drawing fresh attention after an analyst compared its trading setup to past gamma squeeze episodes, pointing to upcoming small cap index inclusion and a relatively small free float. See our latest analysis for Hyperliquid Strategies. The recent spike in speculative interest sits on top of already strong momentum, with 1-day and 7-day share price returns of 16.98% and 30.25%, and a year to date share price return...

Recent performance snapshot Paymentus Holdings (PAY) has drawn investor attention after a period of mixed share performance, with the stock up about 1% over the past day but down around 15% over the past month. Over the past 3 months the stock is lower by roughly 8%, and it is also down around 41% over the past year, while the company reports annual revenue of about US$1.28b and net income of US$74.01m. See our latest analysis for Paymentus Holdings. With the share price at US$23.49, the...

In May 2026, Zoom Communications, Inc. reported first-quarter results showing sales of US$1,239.01 million and net income of US$425.68 million, alongside new revenue guidance for the second quarter and full fiscal year 2027 and an update on its multibillion-dollar share repurchase program. The combination of higher quarterly earnings, stronger per-share profitability, and continued buybacks highlights how Zoom is using its cash generation to support both growth initiatives and capital...

Travere Therapeutics recently received a Notice of Allowance from the USPTO for a patent covering certain methods of using FILSPARI (sparsentan) to treat IgA nephropathy in the US, with protection expected to extend into October 2037 once issued and listed in the FDA’s Orange Book. This added layer of intellectual property protection around FILSPARI’s IgA nephropathy use could strengthen Travere’s competitive moat in rare kidney diseases, even as the product remains subject to strict REMS,...

Keel Infrastructure stock: recent performance snapshot Keel Infrastructure (KEEL) has drawn investor attention after a strong rebound in recent periods, with the stock up 1.1% over the past day, 18.1% over the past week, and 83.8% over the past month. See our latest analysis for Keel Infrastructure. At a share price of $5.68, Keel Infrastructure’s recent 1 month share price return of 83.82% and year to date share price return of 118.46% sit alongside a very large 1 year total shareholder...

Assessing Tarsus Pharmaceuticals after recent share price moves Tarsus Pharmaceuticals (TARS) has seen its stock give back some ground recently, with shares down about 7% over the past month and roughly 22% over the past 3 months, prompting fresh questions from investors. See our latest analysis for Tarsus Pharmaceuticals. At a recent share price of $59.40, the stock has lost momentum in the short term, with weaker 1 week, 1 month and 3 month share price returns contrasting with a much...

Why the Elyra launch matters for Becton Dickinson (BDX) shareholders Becton Dickinson (BDX) has introduced its Elyra Thulium Fiber Laser System for kidney stone care, rounding out its urologic portfolio and drawing fresh attention to how this product expansion might influence the stock. See our latest analysis for Becton Dickinson. At a share price of US$147.12, Becton Dickinson has seen its share price fall over the past quarter and year to date, while the 1 year total shareholder return...

Summit Therapeutics (SMMT) is back in focus after reporting positive overall survival data from its Phase III HARMONi-6 trial in advanced squamous NSCLC, along with strong response rates in a Phase II metastatic colorectal cancer study. See our latest analysis for Summit Therapeutics. Those new ivonescimab data arrive after a steady run in the stock, with a 90 day share price return of 16.08% and a very large 3 year total shareholder return, suggesting momentum has been building around...

If you are wondering whether Flowserve stock around its recent US$75.51 close still offers value, the next sections will walk through what the current price might be implying. The stock has delivered returns of 8.5% over the past 7 days, 5.4% over the last 30 days, 6.7% year to date, 54.9% over 1 year, 130.1% over 3 years and 92.4% over 5 years. This naturally raises questions about what is already priced in and how much risk you are taking on at this level. These moves are occurring...

J.B. Hunt Transport Services (NasdaqGS:JBHT) is being highlighted as a key physical infrastructure company tied to the rise of the AI-driven digital economy. Recent commentary and ETF allocations are pointing to JBHT as a logistics operator benefiting from investor interest in hard asset plays supporting data centers and cloud growth. The focus is shifting beyond earnings figures to the company’s freight network, trucking capacity, and intermodal infrastructure as critical pieces of the real...

In May 2026, ATRenew Inc. reported first-quarter 2026 results showing net income of CNY 135.09 million and basic earnings per share of CNY 0.56, issued second-quarter 2026 revenue guidance of RMB 6,240.0 million to RMB 6,340.0 million indicating year-over-year growth in the mid-twenties percent range, and updated progress on its share repurchase program. Ahead of extending its buyback plan by 12 months, ATRenew had already repurchased 2,320,482 shares for US$10.58 million, which can...

Earnings and Guidance Set the Stage for Agilysys Stock Agilysys (AGYS) is back in focus after reporting fourth quarter and full year results that showed higher revenue and net income year over year, along with new Fiscal 2027 guidance calling for $365 million to $370 million in revenue and at least 30% subscription growth. See our latest analysis for Agilysys. The latest earnings and Fiscal 2027 guidance appear to have shifted sentiment, with a 1 month share price return of 27.58% and a 7 day...

Why D.R. Horton (DHI) is on investors’ radar today D.R. Horton (DHI), the large US homebuilder, continues to draw attention after recent share price moves. The stock is now around $147.09 and has shown mixed returns over the past month and past 3 months. See our latest analysis for D.R. Horton. Recent moves in D.R. Horton’s share price, including a 2.34% 7 day share price gain but a share price return that is down 3.62% over 90 days, contrast with a 27.30% 1 year total shareholder return that...

Target Hospitality Corp. (NasdaqCM:TH) recently completed a secondary offering involving more than 8,000,000 shares. The shares were sold by existing shareholders, with no new capital raised for the company. The transaction led to a significant change in Target Hospitality's shareholder structure. Target Hospitality, which operates in the specialty rental and accommodation services space, now sits in a different ownership mix after this large secondary sale. Because the shares came from...

In May 2026, Prestige Consumer Healthcare’s Dramamine brand introduced two travel-friendly nausea relief options, Less Drowsy Powder stick packs and raspberry-cream Nausea Chewables, promising fast, long-lasting relief and broad retail availability at Amazon, CVS, Walgreens, and Walmart. This expansion of the Dramamine lineup deepens Prestige’s presence in over-the-counter self-care products, aligning with consumer demand for convenient, on-the-go healthcare solutions. We’ll now explore how...

In recent months, Delta Air Lines has pushed further into premium travel, expanding first-class seating, enhancing onboard meals, and rolling out more upscale lounges while leaning on loyalty partnerships to diversify revenue beyond standard economy fares. This premium focus has helped Delta generate around 20% more revenue per seat than many U.S. peers, highlighting how upselling higher-margin products can reshape an airline’s earnings mix and competitive position. Now we’ll examine how...

Recent performance snapshot and why Choice Hotels International (CHH) is on investors’ radar Choice Hotels International (CHH) has drawn attention after a mixed stretch in the stock, with the price falling about 4% over the past week but rising around 8% over the past month. See our latest analysis for Choice Hotels International. At a share price of US$108.88, Choice Hotels International has seen short term momentum cool, with a 1 day share price return down 3.95% and a 7 day share price...

Travel + Leisure (TNL) has been under pressure after Q1 results, as slightly softer EBITDA guidance outweighed in-line revenue and stronger adjusted operating income, even while the company advanced new resort projects and financing moves. See our latest analysis for Travel + Leisure. At a latest share price of US$68.00, Travel + Leisure has seen short term share price momentum soften after Q1 guidance, even though 1 year total shareholder return of 44.88% and 3 year total shareholder return...